ForecastQ
PortfoliosScreenerAbout
Screener > MENS

MENS

Jyong Biotech Ltd. Ordinary Shares
  • Healthcare
  • Biotechnology
  • $151M market cap
Forecast run · Sep 15, 2026Upside rank 153 of 3,136

Model Signal

ForecastQ Daily Probabilities
69.7%
48.0%
52.7%

Analyst Consensus

RecommendationNot rated
Last price$1.99
Price targetNo target

ForecastQ Portfolios

MENS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.

ForecastQ

Quantitative stocks signals powered by AI

Portfolios·Screener·About

The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.

© ForecastQ. All rights reserved.